Sección Reumatología, Hospital de Quilmes, 770, Allison Bell, Quilmes, 1878, Buenos Aires, Argentina.
Instituto de Investigaciones Clínicas, Quilmes, Buenos Aires, Argentina.
Clin Rheumatol. 2023 May;42(5):1479-1483. doi: 10.1007/s10067-023-06581-0. Epub 2023 Mar 28.
Patients with arthralgias who could be at risk of progressing to rheumatoid arthritis (RA) represent a clinical challenge. Recommendations for their management and treatment are lacking. The purpose of the present study was to determine how Argentinean rheumatologists deal with these patients. We developed an anonymous ad hoc survey which was sent to 522 Argentinean rheumatologists. The RA study group of our Argentinean Rheumatology National Society assisted in forwarding the surveys to its members via the internet (e-mail or WhatsApp). The findings of the collected data are presented as descriptive statistics. The questionnaires were completed by 255 rheumatologists (overall response rate of 48.9%), and 97.6% confirmed that their practices had received medical consultations to rule out RA in patients with arthralgias. Ultrasound (US) was the method of first choice (93.7%) as part of the evaluation of these patients. For those in whom US power Doppler signal was present in at least one joint, 93.7% of the participants would start treatment and methotrexate was the first choice (58.1%). In patients with tenosynovitis but no synovitis on US, most rheumatologists would start treatment (89.4%), being NSAIDs the drug of first choice (52.3%). Argentinean rheumatologists evaluate patients with imminent RA and treat them based on their clinical judgment and findings from the US evaluation of affected joints; the drug of first choice for these patients among these rheumatologists was methotrexate. Despite published data of recent clinical trials, recommendations for the management and treatment of these patients are necessary.
关节疼痛且有可能发展为类风湿关节炎 (RA) 的患者是临床面临的挑战。目前缺乏针对此类患者的管理和治疗建议。本研究旨在明确阿根廷风湿病医生如何处理此类患者。我们设计了一份匿名专门调查问卷,并分发给 522 名阿根廷风湿病医生。阿根廷风湿病学会的 RA 研究小组通过互联网(电子邮件或 WhatsApp)协助向其成员转发调查问卷。收集的数据结果以描述性统计呈现。共 255 名风湿病医生完成了调查问卷(总体回复率为 48.9%),97.6%的医生表示其在遇到关节痛患者时会进行医学咨询以排除 RA。超声 (US) 是评估这些患者时的首选方法(93.7%)。对于 US 下至少一个关节存在超声下能量多普勒信号的患者,93.7%的参与者会开始治疗,且甲氨蝶呤是首选药物(58.1%)。对于 US 未见滑膜炎但存在腱鞘炎的患者,大多数风湿病医生会开始治疗(89.4%),首选药物为非甾体抗炎药(52.3%)。阿根廷风湿病医生会根据患者的临床判断和受累关节的 US 评估结果来评估有发展为 RA 风险的患者,并对其进行治疗;对于这些患者,首选药物是甲氨蝶呤。尽管有最近临床试验的相关数据,但仍有必要针对此类患者的管理和治疗提出建议。